Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aethlon Medical has entered into an agreement to initiate the 'first-in-man' clinical study of a medical device to treat the human immunodeficiency virus which causes acquired immune deficiency syndrome.
Subscribe to our email newsletter
The Aethlon Hemopurifier is a medical device created to provide real-time therapeutic filtration of infectious viruses and immunosuppressive proteins. According to the company, the Hemopurifier holds promise to extend the lives of AIDS patients by removing HIV strains that cause drug failure and reducing the presence of viral proteins that kill-off immune cells. The clinical study was approved by the Institutional Ethics Committee at the Jattinder Gambhir Hospital (JG Hospital) in Punjab, India and is anticipated to begin in September, 2008.
The JG Hospital study will evaluate the treatment effectiveness of the Hemopurifier during single-use treatments lasting up to four hours as well as sustained benefit resulting from intermittent treatments administered thrice weekly during extended treatment periods. The successful demonstration of treatment benefit would provide Aethlon with an early commercialization opportunity within India’s practitioner driven medical device marketplace.
Aethlon further disclosed that two candidates remain to be enrolled and treated to complete human safety studies currently being conducted at the Fortis Hospital in Delhi, India. Completion of the study is anticipated, but not required to occur, in advance of the HIV treatment studies to be conducted at the JG Hospital.